A Tale of Two Stories: The Platform Group's Surging Sales Mask a Slumping Stock

The Platform Group reports strong 2025 results with €728M revenue and €55M EBITDA, yet shares fall 9% amid weak consumer sentiment and rate concerns. Pending AEP deal could double revenue to €2B.

The Platform Group (TPG) finds itself in a peculiar spot: its financial scorecard is flashing bright, yet its share price is heading in the opposite direction. The disconnect between a 39% revenue leap and a double-digit stock slide has left investors scratching their heads.

On Tuesday, shares tumbled more than 9% to exactly €3.00, extending the weekly loss to nearly 16%. The stock now sits roughly 45% below its 52-week high, a technical blow that underscores the market's current pessimism.

Operational Engine Fires on All Cylinders

The company's 2025 results tell a story of robust expansion. Revenue surged to €728 million, powered by a disciplined acquisition strategy. Adjusted EBITDA climbed to €55 million, with the Consumer Goods segment leading the charge. A newer division, Optics & Hearing, which was established mid-year, immediately delivered above-average margins, according to analysts.

The group's niche-market approach is paying off. By anchoring itself in specialized areas like eyewear and hearing aids, TPG is building a scalable platform that management believes can sustain momentum.

The Billion-Euro Ambition

The leadership team is sticking to its 2026 guidance, undeterred by the stock's weakness. The target: a billion-euro top line, with adjusted EBITDA landing between €70 million and €80 million. Analysts at First Berlin and NuWays AG view the operational trajectory favorably, emphasizing steady growth in gross merchandise volume as the key valuation driver.

The real game-changer, however, is the pending acquisition of AEP, a B2B pharmaceutical company. Germany's Federal Cartel Office gave the deal the green light in late March, and completion is expected in the second quarter. Management will unveil the financing details by the end of May.

If the transaction closes, TPG's pro-forma revenue would roughly double to around €2 billion. The pharma operations will be housed in a separate division, combining AEP with existing platforms like ApoNow and Doc.Green under dedicated management.

Why the Market Isn't Celebrating

Despite the operational fireworks, the stock is under pressure. NuWays recently slashed its price target from €21 to €17, citing external headwinds: weak consumer sentiment in Germany and a higher interest rate environment. The analysts maintain their buy recommendation, arguing that TPG remains solidly financed, with debt within its target range and operating cash flow comfortably covering interest costs.

The market, for now, is punishing the stock regardless of the underlying progress. The next catalyst for a potential re-rating could come with the release of the AEP financing details later this spring. Until then, TPG's shares may continue to trade in the shadow of macroeconomic uncertainty, even as the company's business engine hums along.